ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)
CUSIP: 00166B105
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 132,496,020
- Total 13F shares
- 41,028,903
- Share change
- -4,604,402
- Total reported value
- $68,515,761
- Put/Call ratio
- 21%
- Price per share
- $1.67
- Number of holders
- 85
- Value change
- -$8,509,648
- Number of buys
- 47
- Number of sells
- 45
Quarterly Holders Quick Answers
What is CUSIP 00166B105?
CUSIP 00166B105 identifies ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00166B105:
Top shareholders of ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| LSV Associates, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,526,963
|
$61,575,751 | — | 13 Dec 2021 | |
| venBio Partners LLC |
13F
|
Company |
7.3%
|
9,699,925
|
$17,653,864 | — | 30 Sep 2024 | |
| FMR LLC |
13F
13D/G
|
Company |
3.4%
from 13D/G
|
5,865,106
|
$10,674,493 | — | 30 Sep 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.2%
|
4,204,735
|
$7,652,618 | — | 30 Sep 2024 | |
| Vivo Capital, LLC |
13F
|
Company |
3%
|
4,034,522
|
$7,342,830 | — | 30 Sep 2024 | |
| Redmile Group, LLC |
13F
|
Company |
2.9%
|
3,836,576
|
$6,982,568 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
2%
|
2,601,776
|
$4,735,232 | — | 30 Sep 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
1.8%
|
2,409,862
|
$4,385,949 | — | 30 Sep 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.5%
|
2,002,374
|
$3,644,321 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.4%
|
1,884,573
|
$3,429,923 | — | 30 Sep 2024 | |
| TANG CAPITAL PARTNERS LP |
13D/G
|
TANG CAPITAL MANAGEMENT, LLC |
6.3%
|
3,296,883
|
$1,681,410 | $0 | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.53%
|
700,847
|
$1,275,772 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.51%
|
671,376
|
$1,221,904 | — | 30 Sep 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.5%
|
660,059
|
$1,201,307 | — | 30 Sep 2024 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.38%
|
509,059
|
$926,487 | — | 30 Sep 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.38%
|
500,500
|
$910,910 | — | 30 Sep 2024 | |
| Sophia Randolph |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
420,711
mixed-class rows
|
$840,334 | — | 14 Aug 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.35%
|
457,717
|
$833,045 | — | 30 Sep 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.32%
|
426,424
|
$773,000 | — | 30 Sep 2024 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.29%
|
383,512
|
$697,992 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.24%
|
320,772
|
$583,806 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.24%
|
319,742
|
$581,931 | — | 30 Sep 2024 | |
| XTX Topco Ltd |
13F
|
Company |
0.24%
|
317,322
|
$577,526 | — | 30 Sep 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.22%
|
290,396
|
$528,520 | — | 30 Sep 2024 | |
| LOS ANGELES CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.19%
|
257,779
|
$469,158 | — | 30 Sep 2024 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.03%
|
41,000
|
$468,000 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.19%
|
256,879
|
$467,519 | — | 30 Sep 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.17%
|
230,875
|
$420,193 | — | 30 Sep 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.17%
|
225,302
|
$410,050 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.13%
|
174,623
|
$317,814 | — | 30 Sep 2024 | |
| Peter S. Garcia |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
mixed-class rows
|
201,516
mixed-class rows
|
$313,511 | — | 14 Aug 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.13%
|
167,831
|
$305,452 | — | 30 Sep 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.12%
|
160,059
|
$291,308 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.12%
|
155,300
|
$282,646 | — | 30 Sep 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.1%
|
137,983
|
$251,129 | — | 30 Sep 2024 | |
| Verition Fund Management LLC |
13F
|
Company |
0.1%
|
133,025
|
$242,106 | — | 30 Sep 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.08%
|
105,894
|
$192,727 | — | 30 Sep 2024 | |
| Graham Capital Management, L.P. |
13F
|
Company |
0.07%
|
96,849
|
$176,265 | — | 30 Sep 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.06%
|
83,042
|
$151,136 | — | 30 Sep 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.06%
|
80,380
|
$146,291 | — | 30 Sep 2024 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.06%
|
74,679
|
$135,916 | — | 30 Sep 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.05%
|
71,730
|
$130,549 | — | 30 Sep 2024 | |
| Aberdeen Group plc |
13F
|
Company |
0.05%
|
66,211
|
$120,504 | — | 30 Sep 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.04%
|
59,502
|
$108,294 | — | 30 Sep 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.04%
|
48,204
|
$88,000 | — | 30 Sep 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.03%
|
42,111
|
$76,636 | — | 30 Sep 2024 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
0.03%
|
41,950
|
$76,349 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.03%
|
40,934
|
$74,501 | — | 30 Sep 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.03%
|
37,646
|
$68,806 | — | 30 Sep 2024 | |
| SHERBROOKE PARK ADVISERS LLC |
13F
|
Company |
0.03%
|
34,373
|
$62,559 | — | 30 Sep 2024 |
Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q4 2024
As of 31 Dec 2024,
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) was held by
85 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
41,028,903 shares.
The largest 10 holders included
venBio Partners LLC, Redmile Group, LLC, TANG CAPITAL MANAGEMENT LLC, MORGAN STANLEY, BlackRock, Inc., MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, FMR LLC, MPM BIOIMPACT LLC, and Almitas Capital LLC.
This page lists
85
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
90
Q4 2024 holders
85
Holder diff
-5
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.